From bench to body: In vivo CAR engineering in the clinic
In vivo CAR engineering is an emerging therapeutic platform for cancer and autoimmune diseases. Enabled by advanced delivery systems such as immune-evasive lentiviral vectors and targeted lipid nanoparticles, this strategy has progressed to early clinical testing, showing initial safety and efficacy. Here, key opportunities and translational hurdles are critically discussed.
Authors
- Yan-Ruide Li (ORCID: https://orcid.org/0000-0002-9858-300X)
- Lili Yang (ORCID: https://orcid.org/0000-0001-6152-9440)
Institutions
- University of California, Los Angeles (US)
Publication Details
- Journal
- Cell Reports Medicine
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.xcrm.2025.102337
- Primary Topic
- RNA Interference and Gene Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00